This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sermonix Pharmaceuticals LLC
Drug Names(s): Oporia, Lasofoxifene, CP336 156
Description: Oporia (Lasofoxifene) is a second-generation non-steroidal estrogen partial agonist. It belongs to the selective estrogen receptor modulators (SERMs) family of drugs.
Ligand and Pfizer
In 1991, Ligand Pharmaceuticals entered into a research and development collaboration with Pfizer to develop therapies for osteoporosis.
Under the terms of the agreement between Ligand and Pfizer, Ligand is entitled to receive an additional milestone upon the first FDA approval of Oporia (lasofoxifene) and, if marketed, royalty payments equal to 6% of net sales of lasofoxifene worldwide for any indication.
In July 2011, Ligand executed a patent license agreement for the exclusive license, under the Licensed Patents, to make, have made, import, use, sell or offer for sale the compound associated with Fablyn. The licenses and rights granted are free of any ongoing obligations to Pfizer.
Ligand and Royalty Pharma
In March 2002, Ligand announced an agreement with Royalty Pharma AG, which purchased rights to a share of future payments from Ligand's collaborative partners' sales of three SERM products (lasofoxifene, bazedoxifene, and...See full deal structure in Biomedtracker
Partners: Royalty Pharma AG Azure Biotech, Inc. Ethicor Pharma Ltd. Ligand Pharmaceuticals, Inc.
Pink Sheet Pfizer/Ligand Fablyn delayed
Pink Sheet ‘Complete Response’ Letters
Additional information available to subscribers only: